An Updated Review of Target‐Specific Oral Anticoagulants Used in Stroke Prevention in Atrial Fibrillation, Venous Thromboembolic Disease, and Acute Coronary Syndromes
Open Access
- 26 September 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 2 (5) , e000136
- https://doi.org/10.1161/jaha.113.000136
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Prevention of VTE in Orthopedic Surgery PatientsChest, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Evidence‐based Venous Thromboembolism Prophylaxis is Associated With a Six‐fold Decrease in Numbers of Symptomatic Venous Thromboembolisms in Rehabilitation InpatientsPM&R, 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEuropean Heart Journal, 2011
- Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolJournal of Thrombosis and Thrombolysis, 2011
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008